August 21, 2007 — FDA clearance of Roche Diagnostics' 9-minute Parathyroid Hormone (PTH) test during parathyroid surgery reportedly provides faster results for surgeons, which may result in shorter surgeries for patients.
The FDA gave Roche Diagnostics clearance in late July to market the test for use during surgery. The test is used on Roche's Elecsys 1010 and 2010 systems and cobas e 411 analyzer and has been available for non-operative use since April.
The test provides quantitative results on the amount of parathyroid hormone in human serum and plasma to diagnose hypercalcemia and hypocalcemia, which helps physicians diagnose parathyroid dysfunction.
Surgeons use the test to establish a PTH baseline on patients with parathyroid adenoma that can cause their parathyroids to malfunction. The test can now be used during surgery at different intervals after the gland is removed to determine whether all the adenoma has been removed and the gland is back to normal function.
"This test provides surgeons with immediate intraoperative feedback," said Herbert Chen, M.D., chief of endocrine surgery for the University of Wisconsin. "It helps surgeons find abnormal glands and helps surgeons confirm what they've removed is abnormal."
Gerard Doherty, M.D., an endocrine surgeon at the University of Michigan, who typically performs five parathyroidectomies on his surgery days, said the test will help him save enough time on surgeries that he will able to perform six parathyroidectomies.
"If we can save enough time in each of those cases to add another surgery, then that's a big benefit," said Doherty.
Doherty estimates the test will help him cut at least five to eight minutes off the length of a typical surgery, and much more time from the surgeries of the patients with more than one impacted gland and the surgeries of the "slow degrader" patients whose PTH levels fall slower after their adenoma is removed.
For more information: www.roche-diagnostics.us
April 18, 2024 
